SmartCella Holding AB
Ricardo Baptista currently serves as Chief Technology Officer at SmartCella Holding AB since April 2024 and as an Advisor for Plurify and NorthX Biologics. Additionally, Ricardo is a Steering Committee Member for Industry Best Practices at the International Society for Stem Cell Research since March 2023 and previously held the position of Chief Technology Officer at Alder Therapeutics until March 2024. Prior roles include Director of CMC & Development at Procella Therapeutics AB and Director of Process & Analytical Development at Cellectis. With a strong background in process development, Ricardo worked at the Cell and Gene Therapy Catapult, along with other positions in project management and development at CCRM and the University of Toronto. Educational credentials include a PhD in Biotechnology and Biochemical Engineering from Instituto Superior Técnico and studies in Protein Biophysics at Aalborg University.
This person is not in any teams
SmartCella Holding AB
SmartCella, founded in 2014, is an innovative biotechnology company based in Stockholm, Sweden. SmartCella’s vision is to combine first-in-class delivery platforms with cutting-edge cell and gene therapies to unleash the full potential of targeted therapies. The company has three main business units, Smartwise, SmartCella Solutions and Procella. Smartwise is developing and manufacturing a first-in-class endovascular delivery device, the Extroducer, that enables direct tissue/organ infusions through the vessel wall directly into to hard-to-reach organs and tumors. There is a significant unmet need in the field of targeted delivery of different types of therapies for regeneration of tissue and for treatment of cancer tumors. Smartwise received regulatory approval from the US FDA for the Extroducer in June 2022 and is now actively out-licensing the technology to global companies with therapies that benefit from direct delivery. SmartCella Solutions create novel mRNA therapies and platforms that enable cell-mediated delivery of protein and mRNA to specific regions, even within organs or microenvironments. A pipeline of projects within regeneration and tolerization, focusing on oncology, is in pre-clinical development. Procella has advanced capabilities within stem cell therapy development and inhouse cGMP manufacturing of cell based therapies, with a proven platform to take stem cell projects from discovery phase to clinical development. A globally licensed cardiac stem cell therapy is entering clinical stages (in collaboration with AstraZeneca) and there is a growing pipeline of projects in different stages of development, with dopamine producing cells for Parkinson´s Disease and our own iMSCs most advanced.